North China Pharmaceutical Company Ltd.SSE: 600812

Announcement on Expected Increase in Annual Performance for 2024

Jan 17, 2025 · Issued by North China Pharmaceutical Company Ltd. via Shanghai Stock Exchange

Filed with SSE · Jan 17, 2025

On 6ix: 6ix.com/news/announcement-on-expected-increase-in-annual-performance-for-2024-15

Announcement on Expected Increase in Annual Performance for 2024

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

North China Pharmaceutical Company Ltd. on 6ix

Earlier from North China Pharmaceutical

Announcement on Receiving the Return of Income from Government Land Purchase, Reserve and Transfer and Signing the Supplementary Contract for Acquisition (Return) of State-owned Land Use Rights of Enterprises and InstitutionsJan 3, 2025
Announcement on Subsidiary's Withdrawal of Drug Registration ApplicationDec 17, 2024

Later from North China Pharmaceutical

Announcement on the Wholly-owned Subsidiary's Passing GMP Compliance InspectionFeb 25, 2025
Announcement on the Wholly-owned Subsidiary's Acquisition of the GMP Compliance Certificate Issued by AEMPS of SpainMar 13, 2025
Announcement on Change of Accounting PoliciesMar 28, 2025
Announcement on Resolution of the 14th Meeting of the 11th Board of SupervisorsApr 24, 2025
Announcement on Pledge Release of Some Shareholders' SharesMay 8, 2025

All North China Pharmaceutical news releases

Follow North China Pharmaceutical into a list and get an email when it puts out news.

Follow North China Pharmaceutical